Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2025 Jun 19:14:e70472.
doi: 10.2196/70472.

Comparing the Accuracy of Different Wearable Activity Monitors in Patients With Lung Cancer and Providing Initial Recommendations: Protocol for a Pilot Validation Study

Roberto M Benzo  1 , Rujul Singh  1 , Carolyn J Presley  2 , Macy K Tetrick  1 , Zachary L Chaplow  3 , Chloe M Hery  1 , Jane Yu  4 , Peter Washington  5 , Frank J Penedo  6   7 , Electra D Paskett  1 , Vipul Lugade  8 , Emma Fortune  9   10
Affiliations
Comparative Study

Comparing the Accuracy of Different Wearable Activity Monitors in Patients With Lung Cancer and Providing Initial Recommendations: Protocol for a Pilot Validation Study

Roberto M Benzo et al. JMIR Res Protoc. .

Abstract

Background: Wearable activity monitors (WAMs) provide insights into physical activity (PA) and are widely used in behavioral interventions and cancer survivorship research. However, validation studies of wearable devices in populations with cancer are scarce, and existing studies using activity monitors in patients with cancer lack standardization. This gap is particularly significant in patients with lung cancer (LC), who often experience unique mobility challenges and gait impairments that may affect device accuracy. This study addresses this gap by validating the Fitbit Charge 6, ActiGraph LEAP, and activPAL3 micro in patients with LC in both laboratory and free-living conditions and developing a standardized framework for assessing wearable devices in populations with cancer and impaired mobility.

Objective: This study aims to validate and compare the accuracy of consumer-grade (Fitbit Charge 6) and research-grade (activPAL3 micro and ActiGraph LEAP) WAMs in patients with LC under both laboratory and free-living conditions. Moreover, this protocol aims to establish standardized procedures that can be adapted for validating current and future generations of wearable devices while accounting for disease-specific factors that may impact measurement accuracy.

Methods: In total, 15 adults diagnosed with LC (stages 1-4) will participate in laboratory and free-living protocols, wearing Fitbit Charge 6, activPAL3 micro, and ActiGraph LEAP devices simultaneously. The laboratory protocol will consist of a series of structured activities, including variable-time walking trials, sitting and standing tests, posture changes, and gait speed assessments. Activities will be video recorded for validation. In the free-living protocol, participants will wear the devices continuously for 7 days except during water-based activities. WAM-based outcome measures will include step count; time spent at light, moderate, and vigorous PA intensity levels; posture; and posture changes (only the activPAL3 micro measured posture). Validated survey instruments will be administered both before and after WAM data collection to control for potential confounding factors that may influence movement patterns and device accuracy. Laboratory-based validity measures will compare WAM data to video-recorded observations. Sensitivity, specificity, positive predictive value, and agreement will also be determined. Free-living agreement between devices will be assessed using Bland-Altman plots, intraclass correlation analysis, and 95% limits of agreement.

Results: Data collection is ongoing, with 11 participants enrolled and 7 (64%) having completed both in-laboratory and free-living protocols. On average, enrolled participants are aged 63.0 (SD 7.8; range 50.0-73.0) years, with 8 (73%) participants being women. Participant enrollment is expected to conclude in mid-2025, and initial findings are expected to be disseminated by the end of 2025.

Conclusions: This is the first study that validates WAM accuracy for populations with LC while providing comprehensive recommendations for future validation studies. This study will provide critical insights into the accuracy and reliability of WAMs for assessing PA in LC survivors, which are essential for interpreting clinical research and informing future interventions.

International registered report identifier (irrid): DERR1-10.2196/70472.

Keywords: ActiGraph; Fitbit; activPAL3 micro; cancer survivorship; consumer technology; digital health; lung cancer; physical activity monitoring; validation study; wearable devices.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: EDP is a multiple principal investigator of grants to the institution not related to this work from Genentech, Pfizer, AstraZeneca, and Guardent Health and is on advisory boards for GSK and Merck. All other authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Data collection procedure. SPPB: Short Physical Performance Battery.
Figure 2
Figure 2
Placement of the Fitbit Charge 6, activPAL3 micro, and ActiGraph LEAP.
Figure 3
Figure 3
In-laboratory data collection. SPPB: Short Physical Performance Battery.
Figure 4
Figure 4
Various data collection setups.
See this image and copyright information in PMC

References

    1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63. doi: 10.3322/caac.21834. https://onlinelibrary.wiley.com/doi/10.3322/caac.21834 - DOI - DOI - PubMed
    1. Huang J, Ostroff J. Overview of approach to lung cancer survivors. UpToDate. [2024-09-17]. https://www.uptodate.com/contents/overview-of-approach-to-lung-cancer-su... .
    1. Physical activity and lung cancer. Association Lung Association. [2024-09-17]. https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cance... .
    1. Cormie P, Zopf EM, Zhang X, Schmitz KH. The impact of exercise on cancer mortality, recurrence, and treatment-related adverse effects. Epidemiol Rev. 2017 Jan 01;39(1):71–92. doi: 10.1093/epirev/mxx007.3760392 - DOI - PubMed
    1. Dinh-Le C, Chuang R, Chokshi S, Mann D. Wearable health technology and electronic health record integration: scoping review and future directions. JMIR Mhealth Uhealth. 2019 Sep 11;7(9):e12861. doi: 10.2196/12861. https://mhealth.jmir.org/2019/9/e12861/ v7i9e12861 - DOI - PMC - PubMed